Q-omics provides the consensus-scored RPP38-DT profile across patient tissues and cancer cell-line models. RPP38-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RPP38-DT is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RPP38-DT RNA expression shows 19,218 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KICH, and UVM as cancer lineages where RPP38-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPP38-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPP38-DT survival associations across molecular data types. RPP38-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPP38-DT RNA expression–survival associations across cancer types. High RPP38-DT expression shows unfavorable associations in ACC, KIRC and UCEC, but favorable associations in PAAD, LUAD and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RPP38-DT RNA expression.
This table summarizes RPP38-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RPP38-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPP38-DT shows lower tumor expression in KICH, THCA, KIRC and BRCA and higher tumor expression in COAD and LIHC. The KICH box plot shows higher RPP38-DT RNA expression in normal versus tumor tissue (log2 FC = −0.443, t-test p < 0.001).
This table shows molecular features associated with RPP38-DT in patient tissues and cancer cell lines. In patient samples, RPP38-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPP38-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
